At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 227 enrolled
Drug / intervention
ACR16 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jul 29, 2008·Updated Aug 31, 2023
In Brief
A Phase 2 clinical trial evaluating ACR16 and Placebo for Huntington Disease. Completed, enrolled 227 participants across 28 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartOct 2008
Primary CompletionJul 2010
TodayJul 2026
First PostedJul 29, 2008
Enrollment StartOct 24, 2008
Primary CompletionJul 26, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.9 years ago
Interventions
ACR16drug
ACR16 will be administered per dose and schedule specified in the arm description.
Placeboother
Placebo matching to ACR16 will be administered per schedule specified in the arm description.